---
title: "Stroke Models"
canonical: "https://www.pharmalegacy.com/indications/cns-disease-models/neuropsychiatric-diseases/addiction/"
lastmod: "2026-08-06T03:42:05+00:00"
generator: "llm-mirrors/1.0.19"
---

# STROKE
PharmaLegacy has the expertise and models you need to advance your stroke pipeline.

PHARMALEGACY HAS THE EXPERTISE AND MODELS YOU NEED TO ADVANCE YOUR STROKE PROGRAMS.

✕

Let PharmaLegacy provide the answers you need.

MODELS / SERVICES

Middle cerebral artery occlusion (MCAO) model of ischemic stroke in rodents

Behavioral assessment battery for middle cerebral artery occlusion (MCAO) stroke models ▼

Case Study - Behavioral assessment battery for middle cerebral artery occlusion (MCAO) stroke models & Endpoint Measurements

PharmaLegacy offers a comprehensive behavioral assessment platform for evaluating functional outcomes in rodent models of ischemic stroke. Our battery combines neurological, motor, cognitive, and histopathological endpoints to provide a multidimensional assessment of stroke severity, recovery, and therapeutic efficacy.
The platform includes cerebral blood flow monitoring using Laser Speckle Contrast Imaging (LSCI), locomotor and exploratory behavior assessment by Open Field Test, gait and motor coordination analysis using CatWalk, and infarct volume evaluation by TTC and Nissl staining. Together, these endpoints enable robust characterization of ischemic injury and functional recovery following middle cerebral artery occlusion (MCAO), supporting both mechanism-of-action studies and preclinical development of novel stroke therapeutics.

Open Field Test & CatWalk Gait Analysis

Collagenase IV-induced model of intracerebral hemorrhage in rat

Photothrombotic stroke model in rodents ▼

Case Study - Photothrombotic stroke model in rodents & Endpoint Measurements

The photothrombotic stroke (PCI) model provides a highly reproducible and spatially controlled approach for inducing focal cerebral ischemia in rodents. By combining a photosensitive dye with targeted cortical illumination, localized vascular occlusion and ischemic injury can be generated with excellent consistency, making this model particularly suitable for mechanistic studies and therapeutic evaluation.
PharmaLegacy offers comprehensive characterization of PCI-induced pathology through histological, vascular, and immunohistochemical analyses. Representative endpoints include infarct visualization, cerebral microvascular integrity, endothelial cell marker analysis (CD31), blood-brain barrier disruption assessment using IgG extravasation, and neuroinflammatory responses within peri-infarct regions. This platform supports studies of ischemic injury, vascular remodeling, neuroprotection, and post-stroke recovery in preclinical CNS drug development.

CD31 & IgG Immunohistochemistry

Middle cerebral artery occlusion (MCAO) M1 and M2 segments in cynomolgus monkey and dog

Enforcing quality in your studies:

FDA Part 11 compliant
Rigorous adherence to international GLP and QA best practices
AAALAC accredited
1500+ validated animal models of disease spanning 100+ indications

Entrust your stroke pipeline to a CRO with a standard of excellence. Entrust it to PharmaLegacy.

✕

Let PharmaLegacy provide the answers you need.

We’re ready when you are.             Tell us your stroke pipeline challenges.

+86-21-6176-5100*8051
+1-617-803-9415

info@pharmalegacy.com

✕

Csv Download